# RGNX catalysts: REGENXBIO Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rgnx/catalysts

> REGENXBIO Inc. (RGNX) has 3 upcoming catalysts. The next is the RGX-202 NDA/BLA submission, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for RGNX?

REGENXBIO Inc. (RGNX) has 3 upcoming catalysts. The next is the RGX-202 NDA/BLA submission, Q1 2027. Press release filed with the SEC (EX-99): "RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027" [Calendar and source filings](https://sec-api.dev/companies/rgnx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-448559, https://www.sec.gov/Archives/edgar/data/1590877/000119312526448559/rgnx-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/rgnx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | REGENXBIO Inc. |
| Ticker | RGNX (Nasdaq) |
| SEC CIK | 1590877 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/rgnx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2023 | [RGX-111 interim data readout](https://sec-api.dev/pdufa/rgx-111) | RGNX |  | completed, positive | "Positive interim data from a Phase I/II trial of RGX-111 were reported in February 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525045585/d909911dex991.htm)) |
| 2025 | [Clemidsogene lanparvovec NDA/BLA submission](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | scheduled | "REGENXBIO retains rights to RGX-121 Priority Review Voucher (PRV) with potential accelerated approval expected in 2025; rolling BLA submission underway" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525005659/d868307dex991.htm)) |
| Mar 2025 | [Clemidsogene lanparvovec NDA/BLA submission](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed | "In March 2025, we submitted a BLA for RGX-121 seeking accelerated approval to the FDA." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526308027/d133519d424b5.htm)) |
| March 13, 2025 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000095017025038711/rgnx-ex99_1.htm)) |
| May 12, 2025 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000095017025069211/rgnx-ex99_1.htm)) |
| 2H 2025 | [Clemidsogene lanparvovec NDA/BLA acceptance](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | scheduled | "This month, REGENXBIO expects the U.S. Food and Drug Administration (FDA) to accept the BLA submitted in March 2025, and potential approval of clemidsogene lanparvovec in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000095017025069211/rgnx-ex99_1.htm)) |
| August 5, 2025 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-ex99_1.htm)) |
| August 18, 2025 | [Clemidsogene lanparvovec PDUFA date](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX | Mucopolysaccharidosis II | scheduled | "On August 18, 2025, REGENXBIO Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has extended the Prescription Drug User Fee Act ("PDUFA") date for the Company's Biologics License Application seeking accelerated approval of clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590877/000095017025109829/rgnx-20250818.htm)) |
| November 6, 2025 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| November 9, 2025 | [Clemidsogene lanparvovec PDUFA date](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | delayed | "In May 2025, the U.S. Food and Drug Administration (FDA) granted priority review of the BLA seeking accelerated approval for clemidsogene lanparvovec for MPS II; Prescription Drug User Fee Act (PDUFA) target action date of November 9, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-ex99_1.htm)) |
| 1H 2026 | [REGENXBIO Inc. topline data readout](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | scheduled | "The pivotal trial is nearly 50% enrolled, and REGENXBIO expects to complete enrollment in the study in 2025, share top line data in the first half of 2026, and submit a BLA under the accelerated approval pathway in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000095017025038711/rgnx-ex99_1.htm)) |
| 1H 2026 | [REGENXBIO Inc. topline data readout](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | scheduled | "REGENXBIO expects to share topline data in the first half of 2026 and submit a Biologics License Application (BLA) under the accelerated approval pathway in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-ex99_1.htm)) |
| February 7, 2026 | [Clemidsogene lanparvovec complete response letter (CRL)](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed, complete response letter | "On February 7, 2026, the Company received a CRL from the FDA regarding the Company's BLA for RGX-121, the Company's investigational gene therapy for Mucopolysaccharidosis type II." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526043342/rgnx-20260207.htm)) |
| February 7, 2026 | [Clemidsogene complete response letter (CRL)](https://sec-api.dev/pdufa/clemidsogene) | RGNX |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 02/07/2026 for BL 125840 to REGENXBIO, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125840_20260207.pdf%22)) |
| February 8, 2026 | [Clemidsogene lanparvovec PDUFA date](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed, complete response letter | "Clemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| February 8, 2026 | [REGENXBIO Inc. PDUFA date](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | scheduled | "FDA PDUFA date is February 8, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| March 5, 2026 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/rgnx-ex99_1.htm)) |
| Q2 2026 | [RGX-202 topline data readout](https://sec-api.dev/pdufa/rgx-202) | RGNX |  | scheduled | "RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/rgnx-ex99_1.htm)) |
| May 2026 | [REGENXBIO Inc. topline data readout](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed, positive | "In May 2026, we announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526308027/d133519d424b5.htm)) |
| May 14, 2026 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526222768/rgnx-ex99_1.htm)) |
| May 14, 2026 | [RGX-202 topline data readout](https://sec-api.dev/pdufa/rgx-202) | RGNX |  | completed, positive | "REGENXBIO today announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, including primary endpoint (n=30 at Week 12), interim safety (n=31), and interim functional data (n=9 at 12 months):1 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526222768/rgnx-ex99_1.htm)) |
| June 23, 2026 | [Surabgene trial start](https://sec-api.dev/pdufa/surabgene) | RGNX |  | completed | "REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/rgnx-ex99_1.htm)) |
| June 29, 2026 | [Surabgene lomparvovec trial start](https://sec-api.dev/pdufa/surabgene-lomparvovec) | RGNX |  | completed | "ROCKVILLE, Md., June 29, 2026 - REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/rgnx-ex99_1.htm)) |
| Q3 2026 | [Clemidsogene lanparvovec NDA/BLA submission](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | scheduled | "We and the FDA aligned on resubmission requirements and we plan to resubmit the RGX-121 BLA in the third quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590877/000119312526336725/rgnx-20260630.htm)) |
| Q3 2026 | [RGX-202 NDA/BLA submission](https://sec-api.dev/pdufa/rgx-202) | RGNX |  | scheduled | "RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/rgnx-ex99_1.htm)) |
| Aug 2026 | [Clemidsogene lanparvovec complete response letter (CRL)](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed, complete response letter | "In August 2026, an amended complaint was filed focusing on interactions with FDA and Company statements prior to the Company's receipt of a Complete Response Letter for RGX-121 in February 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590877/000119312526448581/rgnx-20260930.htm)) |
| August 6, 2026 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/rgnx-ex99_1.htm)) |
| September 2026 | [RGX-202 primary completion](https://sec-api.dev/pdufa/rgx-202) | RGNX | Duchenne Muscular Dystrophy | delayed | "NCT05693142 (AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor REGENXBIO Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05693142)) |
| Q4 2026 | [RGX-202 topline data readout](https://sec-api.dev/pdufa/rgx-202) | RGNX | Duchenne Muscular Dystrophy | scheduled | "Subretinal wet AMD topline pivotal data expected in Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526222768/rgnx-ex99_1.htm)) |
| Q4 2026 | [REGENXBIO Inc. topline data readout](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | scheduled | "Topline results are expected in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| Q4 2026 | [ATMOSPHERE (atmosphere) topline data readout](https://sec-api.dev/pdufa/atmosphere) | RGNX |  | scheduled | "Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526448559/rgnx-ex99_1.htm)) |
| Q4 2026 | [Surabgene lomparvovec topline data readout](https://sec-api.dev/pdufa/surabgene-lomparvovec) | RGNX |  | scheduled | "Surabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/rgnx-ex99_1.htm)) |
| Q4 2026 | [REGENXBIO Inc. topline data readout](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | scheduled | "Enrollment completed in pivotal trials evaluating subretinal delivery of sura-vec in wet AMD; topline data expected Q4 2026 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| November 5, 2026 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526448559/rgnx-ex99_1.htm)) |
| Q1 2027 | [RGX-202 NDA/BLA submission](https://sec-api.dev/pdufa/rgx-202) | RGNX |  | scheduled | "RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526448559/rgnx-ex99_1.htm)) |
| Apr to Jul 2028 | [RGX-121-3102 topline data readout](https://sec-api.dev/pdufa/rgx-121-3102) | RGNX | MPS II; Hunter Syndrome (MPS II) | scheduled | "NCT07236606 (RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor REGENXBIO Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07236606)) |
| April 2028 | [RGX-121-3102 primary completion](https://sec-api.dev/pdufa/rgx-121-3102) | RGNX | MPS II; Hunter Syndrome (MPS II) | scheduled | "NCT07236606 (RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor REGENXBIO Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07236606)) |

## Drugs

- [ATMOSPHERE (atmosphere)](https://sec-api.dev/pdufa/atmosphere): 
- [Clemidsogene](https://sec-api.dev/pdufa/clemidsogene): 
- [Clemidsogene lanparvovec](https://sec-api.dev/pdufa/clemidsogene-lanparvovec): mucopolysaccharidosis ii
- [RGX-111](https://sec-api.dev/pdufa/rgx-111): 
- [RGX-121-3102](https://sec-api.dev/pdufa/rgx-121-3102): MPS II
- [RGX-202](https://sec-api.dev/pdufa/rgx-202): Duchenne Muscular Dystrophy
- [Surabgene](https://sec-api.dev/pdufa/surabgene): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rgnx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RGNX catalysts: REGENXBIO Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rgnx/catalysts

```bibtex
@misc{secapidev_companies_rgnx_catalysts_20261116,
  title        = {RGNX catalysts: REGENXBIO Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rgnx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rgnx_catalysts_20261116","title":"RGNX catalysts: REGENXBIO Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rgnx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
